DCM
SYRE icon

DAFNA Capital Management’s Spyre Therapeutics SYRE Stock Holding History

DAFNA Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,984
Closed -$1.89M – 79
2017
Q4 		$1.89M Hold
13,984
– – 1.02% 32
2017
Q3 		$1.72M Hold
13,984
– – 1.07% 28
2017
Q2 		$1.35M Sell
13,984
-32
-0.2% -$4.42K 0.96% 34
2017
Q1 		$2.61M Hold
14,016
– – 2.21% 13
2016
Q4 		$1.52M Hold
14,016
– – 1.34% 31
2016
Q3 		$2.25M Hold
14,016
– – 1.56% 22
2016
Q2 		$1.7M Buy
+14,016
New +$2.69M 1.35% 21

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return